However, the dichotomy between liquid and solid tumors highlights the question of why hematopoietic tumor cells appear to be more susceptible to HDAC inhibition than normal cells but there is no shown efficacy of HDAC inhibitors against solid tumors. This evidence concerns the gene HDAC9 and neoplasm.